HOME >> BIOLOGY >> NEWS
Tumor suppressor activity of PTEN

Using transgenic mice specifically lacking the PTEN gene in endothelial cells, Dr. Akira Suzuki and colleagues demonstrate that PTEN is required for normal cardiovascular development and that its loss enhanced tumor angiogenesis.

To be published in the September 1 issue of G&D, this new data suggests that PTEN regulates vascular growth factor (VGF) signaling to modulate cardiovascular development and post-natal neovascularization. Loss of PTEN in murine endothelial cells results is dysregulated VGF signaling, enhanced angiogenesis, and accelerated tumor growth.

Their results suggest that an individual who inherits a mutated PTEN allele, such as Cowden disease patient, is not only at risk for additional tumorigenic mutations, but may also experience accelerated growth of tumors due to enhanced angiogenesis. Moreover, the PTEN/PI3K pathway in endothelial cells is an attractive therapeutic target for the treatment of various malignancies.


'"/>

Contact: Heather Cosel
coselpie@cshl.edu
Cold Spring Harbor Laboratory
16-Aug-2005


Page: 1

Related biology news :

1. Tumor painting revolutionizes fight against cancer
2. Tumor vessels identified by unique molecular markers
3. Tumors stopped from spreading to new sites
4. Chest Tumors -- Prevention, treatment and future perspectives
5. Tumor cells evade death through autophagy
6. Tumor-free breast tissue can have precancerous changes
7. Tumor-suppressor gene is critical for placenta development
8. Tumor response may not be best measure of efficacy in non-small cell lung cancer treatment
9. Tumor cells that border normal tissue are told to leave
10. Tumor individuality useful for guiding rational chemotherapeutic decisions
11. Multicenter study nets new lung tumor-suppressor gene

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/31/2020)... ... July 30, 2020 , ... BioFactura, ... contract awarded by the Joint Science & Technology Office—Chemical and Biological Defense (JSTO-CBD) ... develop, optimize, and scale-up a highly efficient mammalian cell culture-based bioprocess suitable to ...
(Date:7/10/2020)... FALLS CHURCH, Va. (PRWEB) , ... July 08, ... ... , The Latest on Cell and Gene Therapy Regulation, An FDAnews Webinar, Wednesday, ... product may need a comparability study, but what is the most effective way ...
(Date:7/1/2020)... N.J. (PRWEB) , ... July 01, 2020 , ... ... announced that it had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in ... the company’s existing Japanese clinical supply facility located in Kakegawa, the new 60,000-square-foot ...
Breaking Biology News(10 mins):
(Date:7/18/2020)... ... July 16, 2020 , ... “We are thrilled to ... Bioactives. “It’s the only technology of its kind on the market and we were ... with the protective capacity of traditional cultured ingredients, creating a natural way to extend ...
(Date:7/18/2020)... TORONTO (PRWEB) , ... July 17, 2020 , ... ... and global consulting firm for the life sciences and food industries, is pleased ... new Director of Clinical Research – Business Development. , Charles is an accomplished ...
(Date:7/10/2020)... , ... July 09, 2020 ... ... company, announced today that Massachusetts Institute of Technology (MIT) has expanded the ... license allows PathSensors to move into the point-of-care diagnostic market, focusing initially ...
(Date:7/10/2020)... ... July 09, 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage ... Allen R. Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. Dr. Nissenson ... product, SBI-101. Dr. Nissenson serves as an Emeritus Professor of Medicine at ...
Breaking Biology Technology:
Cached News: